Identification and characterisation of ruxolitinib resistant mutations in pro-B cell model of high-risk acute lymphoblastic leukaemia

Charlotte EJ Downes; Barbara J McClure; Benjamin  Mayne; John B Bruning; Susan Heatley; Chung Kok; Timothy P Hughes; David T Yeung; Deborah L White

Identification and characterisation of ruxolitinib resistant mutations in pro-B cell model of high-risk acute lymphoblastic leukaemia

Charlotte EJ Downes, Barbara J McClure, Benjamin Mayne, John B Bruning, Susan Heatley, Chung Kok, Timothy P Hughes, David T Yeung, Deborah L White

Research output: Contribution to conference › Poster

Abstract

We modelled and characterised rux resistance in JAK2r B-ALL in vitro to develop therapeutic strategies to overcome or avert resistance in these high-risk patients.

Original language	English
Number of pages	1
Publication status	Published - 2018
Externally published	Yes
Event	Australasian Genomic Technologies Association (AGTA) 2018 Annual Conference - Adelaide, Australia Duration: 4 Nov 2018 → …

Conference

Conference	Australasian Genomic Technologies Association (AGTA) 2018 Annual Conference
Abbreviated title	AGTA 2018 Annual Conference
Country/Territory	Australia
City	Adelaide
Period	4/11/18 → …

Keywords

Identification
Ruxolitinib
Resistant Mutations
Lymphoblastic Leukaemia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

1 Article

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
Downes, C. E. J., McClure, B. J., Bruning, J. B., Page, E., Breen, J., Rehn, J., Yeung, D. T. & White, D. L., 10 Aug 2021, In: npj Precision Oncology. 5, 13 p., 75.
Research output: Contribution to journal › Article › peer-review

Open Access
File
19 Citations (Scopus)

55 Downloads (Pure)

Cite this

Downes, C. EJ., McClure, B. J., Mayne, B., Bruning, J. B., Heatley, S., Kok, C., Hughes, T. P., Yeung, D. T., & White, D. L. (2018). Identification and characterisation of ruxolitinib resistant mutations in pro-B cell model of high-risk acute lymphoblastic leukaemia. Poster session presented at Australasian Genomic Technologies Association (AGTA) 2018 Annual Conference, Adelaide, South Australia, Australia.

@conference{dbb26541b0354286aec5441213452596,

title = "Identification and characterisation of ruxolitinib resistant mutations in pro-B cell model of high-risk acute lymphoblastic leukaemia",

abstract = "We modelled and characterised rux resistance in JAK2r B-ALL in vitro to develop therapeutic strategies to overcome or avert resistance in these high-risk patients. ",

keywords = "Identification, Ruxolitinib, Resistant Mutations, Lymphoblastic Leukaemia",

author = "Downes, {Charlotte EJ} and McClure, {Barbara J} and Benjamin Mayne and Bruning, {John B} and Susan Heatley and Chung Kok and Hughes, {Timothy P} and Yeung, {David T} and White, {Deborah L}",

year = "2018",

language = "English",

note = "Australasian Genomic Technologies Association (AGTA) 2018 Annual Conference, AGTA 2018 Annual Conference ; Conference date: 04-11-2018",

}

Identification and characterisation of ruxolitinib resistant mutations in pro-B cell model of high-risk acute lymphoblastic leukaemia. / Downes, Charlotte EJ; McClure, Barbara J; Mayne, Benjamin et al.
2018. Poster session presented at Australasian Genomic Technologies Association (AGTA) 2018 Annual Conference, Adelaide, South Australia, Australia.

Research output: Contribution to conference › Poster

TY - CONF

T1 - Identification and characterisation of ruxolitinib resistant mutations in pro-B cell model of high-risk acute lymphoblastic leukaemia

AU - Downes, Charlotte EJ

AU - McClure, Barbara J

AU - Mayne, Benjamin

AU - Bruning, John B

AU - Heatley, Susan

AU - Kok, Chung

AU - Hughes, Timothy P

AU - Yeung, David T

AU - White, Deborah L

PY - 2018

Y1 - 2018

N2 - We modelled and characterised rux resistance in JAK2r B-ALL in vitro to develop therapeutic strategies to overcome or avert resistance in these high-risk patients.

AB - We modelled and characterised rux resistance in JAK2r B-ALL in vitro to develop therapeutic strategies to overcome or avert resistance in these high-risk patients.

KW - Identification

KW - Ruxolitinib

KW - Resistant Mutations

KW - Lymphoblastic Leukaemia

M3 - Poster

T2 - Australasian Genomic Technologies Association (AGTA) 2018 Annual Conference

Y2 - 4 November 2018

ER -

Identification and characterisation of ruxolitinib resistant mutations in pro-B cell model of high-risk acute lymphoblastic leukaemia

Abstract

Conference

Keywords

UN SDGs

Fingerprint

Research output

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia

Cite this